These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 33674146)

  • 1. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
    Maclachlan KH; Came N; Diamond B; Roshal M; Ho C; Thoren K; Mayerhoefer ME; Landgren O; Harrison S
    Pathology; 2021 Apr; 53(3):385-399. PubMed ID: 33674146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
    Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
    Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRD Assessment in Multiple Myeloma: Progress and Challenges.
    Bertamini L; D'Agostino M; Gay F
    Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma.
    Bal S; Costa LJ
    Clin Adv Hematol Oncol; 2020 Jan; 18 Suppl 1(1):1-20. PubMed ID: 33843859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurable Residual Disease and Decision-Making in Multiple Myeloma.
    Derman BA; Fonseca R
    Hematol Oncol Clin North Am; 2024 Apr; 38(2):477-495. PubMed ID: 38184470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma.
    Bal S; Weaver A; Cornell RF; Costa LJ
    Br J Haematol; 2019 Sep; 186(6):807-819. PubMed ID: 31364160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease in multiple myeloma: bringing the bench to the bedside.
    Mailankody S; Korde N; Lesokhin AM; Lendvai N; Hassoun H; Stetler-Stevenson M; Landgren O
    Nat Rev Clin Oncol; 2015 May; 12(5):286-95. PubMed ID: 25622976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry.
    Ho C; Syed M; Roshal M; Petrova-Drus K; Moung C; Yao J; Quesada AE; Benhamida J; Vanderbilt C; Liu Y; Zhu M; Yu W; Maciag L; Wang M; Ma Y; Gao Q; Rustad EH; Hultcrantz M; Diamond BT; Zheng-Lin B; Huang Y; Hutt K; Miller JE; Dogan A; Nafa K; Landgren O; Arcila ME
    J Mol Diagn; 2021 Feb; 23(2):181-199. PubMed ID: 33217553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chinese expert consensus on minimal residual disease detection in multiple myeloma based on bone marrow samples (2024)].
    ;
    Zhonghua Xue Ye Xue Za Zhi; 2024 Jun; 45(6):534-541. PubMed ID: 39134483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma.
    Ching T; Duncan ME; Newman-Eerkes T; McWhorter MME; Tracy JM; Steen MS; Brown RP; Venkatasubbarao S; Akers NK; Vignali M; Moorhead ME; Watson D; Emerson RO; Mann TP; Cimler BM; Swatkowski PL; Kirsch IR; Sang C; Robins HS; Howie B; Sherwood A
    BMC Cancer; 2020 Jun; 20(1):612. PubMed ID: 32605647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What to do with minimal residual disease testing in myeloma.
    Manasanch EE
    Hematology Am Soc Hematol Educ Program; 2019 Dec; 2019(1):137-141. PubMed ID: 31808833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical Significance and Detection Techniques of Minimal Residual Disease in Multiple Myeloma-Review].
    Yu Q; Shi JM; Tao Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):961-964. PubMed ID: 28641668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic value of minimal residual disease detection in multiple myeloma].
    Takamatsu H
    Nihon Rinsho; 2015 Jan; 73(1):69-73. PubMed ID: 25626307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
    Waldschmidt JM; Anand P; Knoechel B; Lohr JG
    Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple Myeloma Minimal Residual Disease Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow.
    Langerhorst P; Noori S; Zajec M; De Rijke YB; Gloerich J; van Gool AJ; Caillon H; Joosten I; Luider TM; Corre J; VanDuijn MM; Dejoie T; Jacobs JFM
    Clin Chem; 2021 Nov; 67(12):1689-1698. PubMed ID: 34643690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma.
    Foureau DM; Paul BA; Guo F; Lipford EH; Fesenkova K; Tjaden E; Drummond K; Bhutani M; Atrash S; Ndiaye A; Varga C; Voorhees PM; Usmani SZ
    Clin Lymphoma Myeloma Leuk; 2023 Jan; 23(1):e41-e50. PubMed ID: 36443182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal Residual Disease in Multiple Myeloma: Impact on Response Assessment, Prognosis and Tumor Heterogeneity.
    Berger N; Kim-Schulze S; Parekh S
    Adv Exp Med Biol; 2018; 1100():141-159. PubMed ID: 30411265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal residual disease in multiple myeloma: Benefits of flow cytometry.
    Galtseva IV; Davydova YO; Kapranov NM; Julhakyan HL; Mendeleeva LP
    Int J Lab Hematol; 2018 Feb; 40(1):12-20. PubMed ID: 29058372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
    Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
    Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular detection of minimal residual disease in multiple myeloma.
    Bai Y; Orfao A; Chim CS
    Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.